Sierra Oncology to Hold KOL Call to Discuss Anemia & Transfusion Dependency as Critical Unmet Needs in Myelofibrosis
Event featuring renowned myelofibrosis expert Dr. Ruben Mesa scheduled for 10:00 am ET on Wednesday, May 13th
VANCOUVER, May 7, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that it will host an Analyst & Investor Call to discuss anemia and transfusion dependency, two critical unmet medical needs in treating patients with myelofibrosis, on Wednesday, May 13th at 10:00 am ET. The event will feature a presentation by renowned myelofibrosis expert Dr. Ruben Mesa, Director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center.
"Cytopenias are very common in myelofibrosis, with anemia and the resulting transfusion dependency being strongly associated with poor prognosis and impaired survival in this disease," said Dr. Mesa. "In clinical trials, momelotinib has consistently demonstrated immediate and sustained anemia benefits that manifest in an overall reduced transfusion burden, while sparing platelets and achieving clinically comparable benefits on symptoms and splenomegaly to that of the standard-of-care agent, ruxolitinib. With treatments desperately lacking both for first line patients with either severe anemia or transfusion dependency at presentation, and for the largely cytopenic second line population, momelotinib may offer a potentially important and broadly used new therapeutic option for patients. As such advancing the MOMENTUM Phase 3 trial, which is currently enrolling patients, is a high priority for the MF clinical community."
Dr. Mesa's practice builds on his role as an international expert on myeloproliferative neoplasms (MPNs), a group of bone marrow disorders which include myelofibrosis. He has been involved in MPN research for more than 20 years. He led the development of National Comprehensive Cancer Network's panel guidelines, the first U.S. guidelines on the diagnosis and treatment of myelofibrosis, polycythemia vera and essential thrombocythemia. Dr. Mesa was elected to sit on the National Board of Directors for the Leukemia and Lymphoma Society and sits on the board of the MPN Education Foundation. Dr. Mesa is an investigator in the MOMENTUM Phase 3 trial of momelotinib, which is intended to confirm the array of clinical benefits previously described for the drug candidate.
Dr. Mesa and members of Sierra Oncology's senior management team will be available to answer questions from analysts at the conclusion of the event.
Analyst and Investor Event and Webcast Information
Date and Time: Wednesday, May 13th at 10:00 am ET
Domestic (Toll Free- US): 1-877-407-4018
International (Toll): 1-201-689-8471
Conference ID: 13702348
Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1305667&tp_key=8595ee9eeb
Call registration is available through the Sierra Oncology website at www.sierraoncology.com. An archive of the presentation will be accessible after the event through the Sierra Oncology website.
About Sierra Oncology
Sierra Oncology is a late stage drug development company focused on achieving the successful registration and commercialization of momelotinib, a potent, selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a targeted mechanism of action that enables it to address all three key drivers of myelofibrosis. Momelotinib's differentiated therapeutic profile encompasses robust constitutional symptom improvements, a range of meaningful anemia benefits, including eliminating or reducing the need for frequent blood transfusions, and comparable spleen control to ruxolitinib. More than 1,200 subjects have received momelotinib since clinical studies began in 2009, including more than 820 patients treated for myelofibrosis.
Sierra has launched MOMENTUM, a randomized double-blind Phase 3 clinical trial designed to enroll 180 myelofibrosis patients who are symptomatic and anemic, and who have been treated previously with a JAK inhibitor. The U.S. Food and Drug Administration has granted Fast Track designation to momelotinib. Momelotinib is protected by patents anticipated to provide potential exclusivity to 2040 in the United States and Europe (inclusive of potential Patent Term Extension or Supplementary Protection Certificate).
For more information, please visit www.sierraoncology.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Sierra Oncology's expectations from current data, anticipated clinical development activities, expected success of enrollment of MOMENTUM, and potential benefits of momelotinib. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements are subject to risks and uncertainties, including, among others, the risk that Sierra Oncology's cash resources may be insufficient to fund its current operating plans and it may be unable to raise additional capital when needed, the risk that disruptions and impacts of COVID-19 will be significant and lengthy, Sierra Oncology may be unable to successfully develop and commercialize momelotinib, momelotinib may not demonstrate safety and efficacy or otherwise produce positive results, Sierra Oncology may experience delays in the clinical development of momelotinib, Sierra Oncology may be unable to acquire additional assets to build a pipeline of additional product candidates, Sierra Oncology's third-party manufacturers may cause its supply of materials to become limited or interrupted or fail to be of satisfactory quantity or quality, Sierra Oncology may be unable to obtain and enforce intellectual property protection for its technologies and momelotinib and the other factors described under the heading "Risk Factors" set forth in Sierra Oncology's filings with the Securities and Exchange Commission from time to time. Sierra Oncology undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.
SOURCE Sierra Oncology
Company Codes: NASDAQ-NMS:SRRA